Alpha 2.0
Login Register
» Articles » PMID: 29750107

Changes in Heart Rate in Patients with Type 2 Diabetes Mellitus After Treatment with Luseogliflozin: Subanalysis of Placebo-controlled, Double-blind Clinical Trials

Overview
Journal J Diabetes Investig
Specialty Endocrinology
Date 2018 May 12
PMID 29750107
Citations 16
Authors
Motoaki Sano
Shi Chen
Hisae Imazeki
Hidekazu Ochiai
Yutaka Seino
Affiliations
Soon will be listed here.
Abstract

We evaluated the changes in heart rate on the treatment with SGLT2 inhibitor, luseogliflozin, in Japanese patients with type 2 diabetes mellitus (T2DM). It is suggested that luseogliflozin can effectively decrease in heart rate in patients with higher baseline.

Citing Articles

Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study).

Sugawara M, Fukuda M, Sakuma I, Wakasa Y, Funayama H, Kondo A Diabetes Ther. 2023; 14(9):1517-1535.

PMID: 37410308 PMC: 10363101. DOI: 10.1007/s13300-023-01438-w.

Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease.

Rastogi A, Januzzi Jr J J Clin Med. 2023; 12(8).

PMID: 37109162 PMC: 10143176. DOI: 10.3390/jcm12082824.

Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors.

Pruett J, Romero D, Yanes Cardozo L Front Endocrinol (Lausanne). 2023; 14:951099.

PMID: 36875461 PMC: 9974663. DOI: 10.3389/fendo.2023.951099.

New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure.

Li J, Zhou L, Gong H Front Cardiovasc Med. 2022; 9:903902.

PMID: 36186974 PMC: 9520058. DOI: 10.3389/fcvm.2022.903902.

Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis.

Li M, Yi T, Fan F, Qiu L, Wang Z, Weng H Cardiovasc Diabetol. 2022; 21(1):139.

PMID: 35879763 PMC: 9317067. DOI: 10.1186/s12933-022-01574-w.

References
1.
Seino Y, Sasaki T, Fukatsu A, Sakai S, Samukawa Y . Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study. Curr Med Res Opin. 2014; 30(7):1219-30. DOI: 10.1185/03007995.2014.901943. View
2.
Hillis G, Hata J, Woodward M, Perkovic V, Arima H, Chow C . Resting heart rate and the risk of microvascular complications in patients with type 2 diabetes mellitus. J Am Heart Assoc. 2013; 1(5):e002832. PMC: 3541618. DOI: 10.1161/JAHA.112.002832. View
3.
Ruiz J, Monbaron D, Parati G, Perret S, Haesler E, Danzeisen C . Diabetic neuropathy is a more important determinant of baroreflex sensitivity than carotid elasticity in type 2 diabetes. Hypertension. 2005; 46(1):162-7. DOI: 10.1161/01.HYP.0000169053.14440.7d. View
4.
Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y . Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study. Curr Med Res Opin. 2014; 30(7):1231-44. DOI: 10.1185/03007995.2014.909390. View
5.
Huggett R, Scott E, Gilbey S, Stoker J, Mackintosh A, Mary D . Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation. 2003; 108(25):3097-101. DOI: 10.1161/01.CIR.0000103123.66264.FE. View